# Vor Biopharma Inc.: overview

VOR · Nasdaq · CIK 1817229 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vor.md) · [Financials](/companies/vor/financials.md) · [Filings](/companies/vor/filings.md) · [Insiders](/companies/vor/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | not reported | [(5.21)](/filings/0001193125-26-220689.md) | [(251.24)](/filings/0001193125-26-343607.md) | [(121.63)](/filings/0001193125-26-439905.md) | not reported | [(5.11)](/filings/0001193125-26-220689.md) | [(1.16)](/filings/0001193125-26-343607.md) | [(1.45)](/filings/0001193125-26-439905.md) |
| Free cash flow | $m | [(24.1) d](/filings/0001193125-26-130451.md) | [(31.3)](/filings/0001193125-26-220689.md) | [(35.3) d](/filings/0001193125-26-343607.md) | [(53.9) d](/filings/0001193125-26-439905.md) | [(23.1) d](/filings/0001193125-26-130451.md) | [(38.3)](/filings/0001193125-26-220689.md) | [(25.5) d](/filings/0001193125-26-343607.md) | [(32.8) d](/filings/0001193125-26-439905.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(2.10)](/filings/0000950170-23-009472.md) | [(2.33)](/filings/0000950170-24-034146.md) | [(1.75)](/filings/0000950170-25-042623.md) | [(34.03)](/filings/0001193125-26-130451.md) | [(70.50)](/filings/0001193125-26-130451.md) |
| Free cash flow | $m | [(73.0)](/filings/0000950170-23-009472.md) | [(93.6)](/filings/0000950170-24-034146.md) | [(101)](/filings/0000950170-25-042623.md) | [(99.9)](/filings/0001193125-26-130451.md) | [(144)](/filings/0001193125-26-130451.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vor/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $104.4m | 5,673,078 |  | Unchanged |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $90.8m | 4,932,149 |  | Added +3,392,479 |
| [FCPM III SERVICES B.V.](/funds/2013410.md) | 2026-06-30 | $75.8m | 4,117,354 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $63.8m | 3,468,107 |  | Added +2,673,348 |
| [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $56.0m | 3,041,719 |  | Unchanged |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $48.2m | 2,616,336 |  | Added +1,497,878 |
| [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $46.8m | 2,543,939 |  | Unchanged |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $44.2m | 2,402,095 |  | Reduced −3,002,903 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $38.4m | 2,084,328 |  | Added +651,048 |
| [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $35.4m | 1,925,066 |  | Unchanged |

## Recent filings

[All 460 filings](/companies/vor/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-30 | 08:01 ET | [10-Q](/filings/0001193125-26-439905.md) | Quarterly report, period 2026-09-30 | 0001193125-26-439905 |
| 2026-08-11 | 09:30 ET | [10-Q](/filings/0001193125-26-343607.md) | Quarterly report, period 2026-06-30 | 0001193125-26-343607 |
| 2026-07-21 | 16:55 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000197.md) | Ownership report, active investor, amended | 0001346824-26-000197 |
| 2026-07-07 | 16:04 ET | [8-K](/filings/0001193125-26-297454.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-297454 |
| 2026-06-12 | 16:11 ET | [8-K](/filings/0001193125-26-269431.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-269431 |
| 2026-06-08 | 16:01 ET | [8-K](/filings/0001193125-26-261661.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-261661 |
| 2026-05-13 | 08:31 ET | [10-Q](/filings/0001193125-26-220689.md) | Quarterly report, period 2026-03-31 | 0001193125-26-220689 |
| 2026-04-27 | 16:00 ET | [DEF 14A](/filings/0001193125-26-181883.md) | Proxy statement, period 2026-04-23 | 0001193125-26-181883 |
| 2026-04-21 | 19:05 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000113.md) | Ownership report, active investor, amended | 0001346824-26-000113 |
| 2026-04-15 | 17:31 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000107.md) | Ownership report, active investor, amended | 0001346824-26-000107 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-130451.md), filed Mar 30, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1817229
- Tickers: VOR
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: not reported
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 31, 2026, 03:06 ET. No prices; not investment advice.